Group 1 - The core point of the article is that Four Seasons Pharmaceutical (00460.HK) announced the final analysis results of its self-developed CDK2/4/6 inhibitor, Pyrocil, from the Phase III BRIGHT-2 clinical study, which has been published in the prestigious medical journal JAMA Oncology [1] - The BRIGHT-2 study is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical trial conducted in China, aimed at evaluating the efficacy and safety of Pyrocil in combination with Fulvestrant for patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who have progressed after prior endocrine therapy [1] - The study was led by Academician Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences and involved 64 hospitals across the country [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 吡洛西利聯合氟維司群治療HR+╱HER2－晚 期 乳 腺 癌 III期 臨 床 研 究（BRIGHT-2）最 終 分 析 結 果 於 國 際 頂 尖 期 刊《JAMA Oncology》發 表 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒竹生物」）（股 份 代 號：02575.HK）自 主 研 發 的 新 型CDK2/4/6抑 制劑吡洛西利的III期BRIG ...

Group 1 - The company SiHuan Pharmaceutical (00460) announced that its non-wholly owned subsidiary, XuanZhu Biotechnology Co., Ltd. (stock code: 02575.HK), has successfully completed the enrollment of 500 participants in the Phase III clinical trial for its innovative drug, Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei), aimed at treating adult reflux esophagitis (RE) in China [3] - The Phase III clinical trial is a multi-center, randomized, double-blind, double-dummy, positive drug parallel-controlled key study designed to evaluate the efficacy and safety of Anaprazole Sodium Enteric-Coated Tablets in adult participants with reflux esophagitis in China [3] - The primary clinical endpoint of the trial is the cure rate of reflux esophagitis in participants assessed by endoscopy after the treatment period, compared to a positive control drug within 8 weeks of treatment; secondary endpoints include the cure rate at week 4, severity and frequency of primary symptoms (heartburn and reflux) compared to baseline at weeks 4 and 8, among other multidimensional efficacy indicators [3]

Core Viewpoint - The announcement highlights the successful completion of patient enrollment for a Phase III clinical trial of Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiewei®) for the treatment of adult reflux esophagitis (RE) in China, involving 500 participants [1] Group 1: Clinical Trial Details - The Phase III clinical trial is a multi-center, randomized, double-blind, parallel-group study designed to evaluate the efficacy and safety of Anaprazole Sodium Enteric-Coated Tablets in adult patients with reflux esophagitis in China [1] - The primary clinical endpoint is the cure rate of reflux esophagitis as assessed by endoscopy compared to a positive control drug after an 8-week treatment period [1] - Secondary endpoints include the cure rate at week 4, changes in the severity and frequency of primary symptoms (heartburn and regurgitation) from baseline at weeks 4 and 8, and various efficacy metrics [1] Group 2: Safety Indicators - Safety indicators focus on the types, incidence, and severity of adverse events occurring during the trial [1]

Core Viewpoint - The announcement highlights the successful completion of the Phase III clinical trial for Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei®) developed by Xuan Zhu Bio-Tech Co., Ltd., a non-wholly owned subsidiary of Sihuan Pharmaceutical (00460), for the treatment of adult reflux esophagitis in China [1] Group 1 - The Phase III clinical trial involved a total of 500 participants and was designed as a multi-center, randomized, double-blind, parallel-group study [1] - The primary clinical endpoint of the trial was the cure rate of reflux esophagitis in participants, assessed via endoscopy after an 8-week treatment period compared to a positive control drug [1] - Secondary endpoints included the cure rate at week 4, changes in the severity and frequency of primary symptoms (heartburn and reflux) from baseline at weeks 4 and 8, and various efficacy indicators [1] Group 2 - Safety indicators focused on the types, incidence, and severity of adverse events occurring during the trial [1]

Core Viewpoint - The completion of the Phase III clinical trial for Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiewei®) by the subsidiary Xuan Zhu Bio marks a significant milestone in the treatment of adult reflux esophagitis in China, with 500 participants successfully enrolled in the study [1] Group 1: Clinical Trial Details - The Phase III clinical trial is a multi-center, randomized, double-blind, and positive drug parallel-controlled study [1] - The primary clinical endpoint is the healing rate of reflux esophagitis in participants compared to a positive control drug after an 8-week treatment period [1] - Secondary endpoints include the healing rate at week 4, severity and frequency of primary symptoms (heartburn and reflux) compared to baseline at weeks 4 and 8, and various efficacy indicators [1] Group 2: Safety Assessment - Safety indicators focus on the types, incidence, and severity of adverse events occurring during the trial [1]

Core Viewpoint - The completion of the Phase III clinical trial for Annelazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei®) by the subsidiary Xuan Zhu Bio of the company is a significant milestone in the treatment of adult reflux esophagitis in China, involving 500 participants [1] Group 1: Clinical Trial Details - The Phase III clinical trial is a multi-center, randomized, double-blind, and positive drug parallel-controlled study [1] - The primary clinical endpoint is the healing rate of reflux esophagitis in participants compared to a positive control drug after an 8-week treatment period [1] - Secondary endpoints include the healing rate at week 4, severity and frequency of primary symptoms (heartburn and reflux) compared to baseline at weeks 4 and 8, and various efficacy indicators [1] Group 2: Safety Indicators - Safety indicators focus on the types, incidence, and severity of adverse events occurring during the trial [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 安 奈 拉 唑 鈉 腸 溶 片（安 久 衛®）治 療 反 流 性 食 管 炎 中 國III期臨床試驗完成全部受試者入組 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒竹生物」」）（股 份 代 號：02575.HK）自 主 研 發 的 創 新 藥 安 奈 拉 唑 鈉 腸 溶 片（商 品 名：安 久 衛®）用 於 治 療 成 人 反 流 性 食 管 炎（「RE」） ...

Group 1 - The company, Four Seasons Pharmaceutical (00460.HK), announced that it will hold a board meeting on March 31, 2026, to approve the annual performance for the year ending December 31, 2025, and discuss the potential distribution of a final dividend [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 董事會會議通知 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 六 年 三 月 三 十 一 日（星 期 二）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 業 績 及 其 發 佈，並 討 論 及 通 過（如 適 用）派 發 末 期 股 息。 承董事會命 四環醫藥控股集團有限公司 主席兼執行董事 於 本 公 告 日 期，本 公 司 的 執 行 董 事 為 車 馮 升 醫 生（主 席）、郭 維 ...